Click here to receive MS news via e-mail
AD (advisory) BOARD RECRUITMENT INFO
A pharmaceutical/biotech company is in the process of developing
a new potential multiple sclerosis (MS) therapy and will be hosting a small
Patient/Care-partner Advisory Board meeting on Thursday, November 3, 2016 in
Chicago, IL.
a new potential multiple sclerosis (MS) therapy and will be hosting a small
Patient/Care-partner Advisory Board meeting on Thursday, November 3, 2016 in
Chicago, IL.
At this one-day meeting, people with a diagnosis of primary
progressive multiple sclerosis (PPMS) and their Support partners will be
invited to share their experiences and challenges living with PPMS. This advice
will inform the pharmaceutical/biotech company’s work in providing information
about the product and appropriately engaging with the MS community.
progressive multiple sclerosis (PPMS) and their Support partners will be
invited to share their experiences and challenges living with PPMS. This advice
will inform the pharmaceutical/biotech company’s work in providing information
about the product and appropriately engaging with the MS community.
The pharmaceutical/biotech company will reimburse the travel
expenses of invited participants, and provide an honorarium as thanks for their
time and participation.
expenses of invited participants, and provide an honorarium as thanks for their
time and participation.
Participants must:
- be between the ages of 18 and 55
- have a diagnosis (made by a physician)
of PPMS for 3 to 10 years - not currently be participating in an MS
drug clinical trial - be interested in participating, with or
without a care-partner; and - be willing and able to travel to
Chicago, IL, for a one-day meeting on Thursday, November 3rd. The
meeting will be held at a hotel near the Chicago O’Hare International
Airport.
If you are interested in attending, please contact Sam Wunderle
at Stem Scientific by email or phone.
at Stem Scientific by email or phone.
201-271-6160
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews